I am not sure where it was agreed (unlikely the pub), but I do know that it was not a mitigation strategy to pump the SP, but a serious effort aimed at achieving a transaction at a price that reflected the board's (at the time) opinion of the value of Bisantrene. Thankfully no transaction eventuated.
We should remember that Merck once had Keytruda on their outsource/disposal list with a zero dollar cost. Wouldn’t it have been great to have picked up Keyruda for nothing - being able to buy Bisantrene for $3 million (the price of RAC when I started buying on market) is in the same league.
Ann: Change in substantial holding, page-108
-
- There are more pages in this discussion • 78 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.050(3.17%) |
Mkt cap ! $259.9M | |||
| Open | High | Low | Value | Volume |
| $1.58 | $1.59 | $1.51 | $174.6K | 113.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2372 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.59 | 141 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| RAC (ASX) Chart |